TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2905803
Drug: Buspirone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (5 or 10 mg)
Study: 28838263
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 10-15 mg/week for minimum 12 weeks
Study: 26520413
Drug: Prebiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic supplementation with inulin (10 g/day)
Study: 18823395
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg zoledronate i.v. every 3 months for 2 years (8 infusions)
Study: 18823395
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo) every 3 months for 2 years (8 infusions)
Study: 15125825
Drug: Insulin in
Normalized name: insulin inhalation chamber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin in addition to unchanged oral hypoglycemic medication (IC group)
Study: 15125825
Drug: Insulin monotherapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin monotherapy (IM group)
Study: 12563567
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 2 mg o.d.
Study: 12563567
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 4 mg o.d.
Study: 12563567
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 8 mg o.d.
Study: 28974305
Drug: Ultrasound-guided SGB
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided SGB (n = 20) with a 6-mL injection of 1% lidocaine
Study: 28974305
Drug: Sham procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sham procedure (n = 20) with a 6-mL injection of 0.9% saline
Study: 27358638
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment intervention (Control)
Study: 22214287
Drug: Invasive strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive strategy (stenting of the infarct-related coronary artery with abciximab as adjunct treatment)
Study: 31982398
Drug: Exogenous progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Exogenous progesterone administered intraperitoneally
Study: 31035017
Drug: ARD-3150 (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARD-3150 (inhaled liposomal ciprofloxacin)
Study: 14681846
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g butter + 40 g alcohol + 50 g carbohydrate
Study: 14681846
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g butter alone
Study: 14681846
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g butter + 120 g carbohydrate
Study: 9833177
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 8 mg o.i.d. (increased to 16 mg o.i.d. if necessary)
Study: 3154330
Drug: Chlorthalidone 25
Normalized name: chlorthalidone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25 mg daily
Study: 3154330
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Nifedipine + Chlorthalidone)
Study: 25259674
Drug: Levomilnacipran ER
Normalized name: levomilnacipran Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levomilnacipran ER (40, 80, 120 mg/day)
Study: 16505046
Drug: Diphenhydramine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (1.0 mg/min over 50 minutes)
Study: 9062618
Drug: Intravenous oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxycodone hydrochloride 0.05 mg/kg
Study: 9062618
Drug: Intranasal oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal oxycodone hydrochloride 0.1 mg/kg
Study: 8330469
Drug: Low-dose enteric-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose enteric-coated aspirin (100 mg daily)
Study: 3777411
Drug: 1% methohexital
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% methohexital solution at 20 mg/kg body wt.
Study: 3777411
Drug: 1% methohexital
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% methohexital solution at 25 mg/kg body wt.
Study: 3777411
Drug: 5% methohexital
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% methohexital solution
Study: 3777411
Drug: 1% methohexital
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% methohexital solution at 15 mg/kg body wt.
Study: 3777411
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg body wt. and 10 mg/kg body wt. dosages
Study: 29266290
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) treatment combined with fractional CO2 laser therapy
Study: 29266290
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) administration after laser irradiation
Study: 28735763
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no PRP treatment)
Study: 27130705
Drug: Eplerenone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (25 mg every other day, increased to 25 mg once daily on Day 30, and to 50 mg once daily on Day 60)
Study: 27130705
Drug: Finerenone (2.5→5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone (2.5→5, 5→10, 7.5→15, 10→20, and 15→20 mg, uptitrated on Day 30)
Study: 27130705
Drug: Finerenone (10→20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone (10→20 mg)
Study: 11775204
Drug: Intravenous mannitolum
Normalized name: Mannitolum
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous mannitolum 250 ml
Study: 11775204
Drug: Intravenous albumin
Normalized name: albumin human, USP Injection [Albuminar]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous albumin 20 g
Study: 8858219
Drug: IGF‐I (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF‐I (8 micrograms.kg‐1.h‐1) for 5 days by continuous subcutaneous infusion
Study: 6734705
Drug: Piretanide (12,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide (12, 24, 48, 96 mg)
Study: 6734705
Drug: Piretanide (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide (48 mg and 96 mg)
Study: 26869012
Drug: Quetiapine 150
Normalized name: quetiapine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 150 mg XL for seven nights
Study: 26869012
Drug: Quetiapine 150
Normalized name: quetiapine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 150 mg XL
Study: 25081182
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm of the Costa Rica Vaccine Trial (2004-2010)
Study: 22891782
Drug: Intravascular laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular laser irradiation of blood (ILIB) therapy for 1 hour daily for 15 days over 3 weeks
Study: 11789263
Drug: Intravascular laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular laser irradiation of blood (ILIB) therapy
Study: 19104122
Drug: Topical negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical negative pressure (TNP) wound closure using a locally constructed device
Study: 2287558
Drug: Aspirin 1000
Normalized name: aspirin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 1000 mg
Study: 2324921
Drug: Acetaminophen 500
Normalized name: acetaminophen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 500 mg
Study: 16154478
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active treatments (Aspirin and Acetaminophen)
Study: 12573299
Drug: Methyltestosterone (MT)
Normalized name: Methyltestosterone
DrugBank: Methyltestosterone (DB06710)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyltestosterone (MT) 40 mg/day for 3 days, then 240 mg/day for 3 days
Study: 1683189
Drug: Levocabastine nasal
Normalized name: levocabastine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine nasal spray (0.5 mg/mL)
Study: 1683189
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate nasal spray (20 mg/mL)
Study: 6793058
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplements (1000 iu daily)
Study: 25803626
Drug: Synbiotics (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotics (Lactobacillus acidophilus 10, 1 × 10(9)CFU; Lactobacillus rhamnosus HS 111, 1 × 10(9) CFU; Lactobacillus casei 10, 1 × 10(9) CFU; Bifidobacterium bifidum, 1 × 10(9)CFU; fructooligosaccharides (FOS) 100 mg), administered twice daily for 14 days
Study: 21076316
Drug: CVD risk
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD risk reduction intervention (16 weeks) including 150 minutes of regular exercise per week, 200-300 kcal reduced daily diet, one-on-one psychobehavioral counseling, and telephone coaching
Study: 19784816
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/day for 6 months
Study: 17258855
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg OD
Study: 17258855
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alfuzosin and sildenafil
Study: 15197377
Drug: Consultation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consultation and training provided by nurse educators on best practice protocols for prevention of decline in activities of daily living, pain, and depression.
Study: 11845946
Drug: Adapalene cream
Normalized name: Adapalene
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene cream 0.1%
Study: 14700217
Drug: Tretinoin formulations
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin formulations (Avita cream 0.025%, Retin‐A cream 0.025%, Retin‐A cream 0.05%, Retin‐A Micro gel 0.1%, and generic cream 0.025%)
Study: 7605761
Drug: Low-dose epinephrine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose epinephrine (EPI) intravenous infusion
Study: 7605761
Drug: Phenylephrine (PHE)
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine (PHE) intravenous infusion
Study: 2194537
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose of radiotherapy
Study: 2194537
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of endocrine treatment
Study: 2194537
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of cytostatic treatment
Study: 85872
Drug: Pectin added
Normalized name: Pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectin added to glucose solution
Study: 85872
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum and pectin added to paracetamol
Study: 11465516
Drug: Testosterone enanthate,
Normalized name: Testosterone Enanthate, enanthate 200 mg/mL intramuscular solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate, 200 mg, weekly intramuscular injections
Study: 23788517
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg Bacopa monnieri (BM)
Study: 23788517
Drug: 640 mg
Normalized name: glycerin 1640 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 640 mg Bacopa monnieri (BM)
Study: 19217460
Drug: Low-dose pravastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pravastatin (10 mg/d)
Study: 19217460
Drug: High-dose pravastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pravastatin (40 mg/d)
Study: 7868711
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg itraconazole daily
Study: 15196159
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg itraconazole daily
Study: 12068841
Drug: Sublingual apomorphine
Normalized name: apomorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual apomorphine 2 mg
Study: 12068841
Drug: Sublingual apomorphine
Normalized name: apomorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual apomorphine 3 mg
Study: 12068841
Drug: Sublingual apomorphine
Normalized name: apomorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual apomorphine (general)
Study: 12068841
Drug: Sublingual apomorphine
Normalized name: apomorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual apomorphine
Study: 9793702
Drug: Sumatriptan nasal
Normalized name: SUMAtriptan nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan nasal spray (20 mg/dose)
Study: 9793702
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of sumatriptan
Study: 7620630
Drug: Laufband therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laufband therapy (LB) with body weight support (BWS) and assisted limb movements
Study: 7620630
Drug: Laufband therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laufband therapy (LB)
Study: 2515583
Drug: Recombinant interferon-Roferon
Normalized name: interferon gamma, porcine recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon-Roferon (R-IFN) applied as ointment, 20,000 IU/g
Study: 2515583
Drug: Human leukocyte
Normalized name: Human leukocyte antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human leukocyte interferon-Ginterferon (G-IFN) applied as ointment, 10,000 IU/g
Study: 2515583
Drug: Both R-IFN
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both R-IFN and G-IFN
Study: 31765640
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo plus education only
Study: 31765640
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo plus biofeedback
Study: 31765640
Drug: Responders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responders to fecal incontinence treatment
Study: 30704287
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg od plus a P2Y12 inhibitor (group 1)
Study: 30704287
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg bid plus dual antiplatelet therapy (group 2)
Study: 30704287
Drug: Warfarin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin plus dual antiplatelet therapy (group 3)
Study: 25565885
Drug: Pregabalin 300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300 mg/d
Study: 24415567
Drug: Pregabalin 600
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 600 mg/d
Study: 27531675
Drug: Pregabalin flexible
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin flexible dose (150-600 mg/d)
Study: 24399120
Drug: Prulifloxacin 600
Normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin 600 mg for 15 days + Serenoa repens extract for 8 weeks
Study: 24399120
Drug: Prulifloxacin 600
Normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin 600 mg for 15 days
Study: 21871782
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin 500mg three times daily for 2 days, then oral amoxicillin for 3 more days
Study: 21871782
Drug: Intravenous ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ampicillin 1g four times daily for 2 days, then oral amoxicillin for 3 more days
Study: 17599747
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment (10 mg bipuvicaine, 40 mg triamcinolone hexacetonide)
Study: 17599747
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 mg bipuvicaine, 2 ml saline)
Study: 11593094
Drug: Felodipine (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (with possible additional medications: ACE-inhibitor, beta-blocker, diuretic)
Study: 8017036
Drug: Psychological Relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological Relaxation Therapy (PRT)
Study: 8017036
Drug: No Psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Psychological Relaxation Therapy (Control)
Study: 2542629
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg daily) with flunarizine (10 mg daily)
Study: 30039986
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 6 mg·kg-1
Study: 28517955
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical therapy (IMT) with prompt revascularization
Study: 25376536
Drug: Dental floss
Normalized name: dental floss
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental floss impregnated with 5% chlorhexidine gluconate, used twice a day for 15 days
Study: 25376536
Drug: Waxed floss
Normalized name: Candelilla Wax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waxed floss without impregnation, used twice a day for 15 days
Study: 19454860
Drug: Multiple-dose LRPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose LRPT 40 mg/d for 12 days with coadministered single-dose warfarin 30 mg
Study: 19454860
Drug: Single-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose warfarin 30 mg alone
Study: 17678656
Drug: CIMT (constraint‐induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIMT (constraint‐induced movement therapy)
Study: 18642635
Drug: Traditional intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional intervention (control treatment)
Study: 15201103
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with ultrasound therapy
Study: 12759515
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg/day plus acenocoumarol at a targeted INR of 2.4‐3.6
Study: 12759515
Drug: Acenocoumarol alone
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acenocoumarol alone at the same dosage
Study: 7907073
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (3 MU 3 times weekly for 6 months)
Study: 7907073
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (12-month course: 3 MU 3 times weekly for the first 6 months, 2 MU for the following 3 months, and 1 MU for the last 3 months)
Study: 2766862
Drug: High-dose cis-platinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cis-platinum (120 mg/m2) combined with cyclophosphamide (600 mg/m2)
Study: 2766862
Drug: Low-dose cis-platinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose cis-platinum (60 mg/m2) combined with cyclophosphamide (600 mg/m2)
Study: 19348
Drug: Gastropulgit Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastropulgit Gel (liquid antacid)
Study: 22445501
Drug: Interleukin-1 receptor
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Interleukin-1 receptor antagonist (IL-1Ra)
Study: 16182635
Drug: Interview-administered dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interview-administered dietary recall (FIAS)
Study: 10524635
Drug: Glycyrrhizin (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhizin (group G)
Study: 10524635
Drug: Glycyrrhizin plus
Normalized name: glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhizin plus ursodeoxycholic acid (group G+U)
Study: 7014277
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oxatomide b.i.d.
Study: 28681387
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (classical oral motor exercises)
Study: 15226754
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (15 mg iron and multivitamins)
Study: 12553109
Drug: roxithromycin 300
Normalized name: roxithromycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin 300 mg once daily for 28 days
Study: 2465265
Drug: Inosine pranobex
Normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine pranobex 3 g a day for four weeks
Study: 31539674
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure therapy (with or without virtual reality)
Study: 28864749
Drug: Wuzhi tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuzhi tablet co-administration with tacrolimus